Review: Peroxisome proliferator-activated receptor γ and adipose tissue - Understanding obesity-related changes in regulation of lipid and glucose metabolism

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 2, 2007, Pages 386-395

  Sharma, Arya M ^a   Staels, Bart ^b,c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b INSTITUT PASTEUR DE LILLE   (France)

^c INSERM   (France)

^d UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSINOGEN; APOLIPOPROTEIN B; AUTACOID; FATTY ACID; GLITAZONE DERIVATIVE; INTERLEUKIN 6; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; ROSIGLITAZONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ADIPOSE TISSUE; ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; BODY FAT DISTRIBUTION; CELL STRUCTURE; CYTOKINE PRODUCTION; DIABETIC OBESITY; DRUG MECHANISM; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FATTY LIVER; GENE DELETION; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; MEDIATOR RELEASE; METABOLIC DISORDER; METABOLIC REGULATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SICK FAT CELL SYNDROME; UPREGULATION; WEIGHT GAIN;

EID: 33847006604     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1268     Document Type: Review

References (111)

1. Grundy SM 2004 Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89:2595-2600
2. Wajchenberg BL 2000 Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697-738
3. Sharma AM 2002 Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord 26(Suppl 4):S5-S7
4. Klaus S 2004 Adipose tissue as a regulator of energy balance. Curr Drug Targets 5:241-250
5. Trayhurn P, Wood IS 2004 Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347-355
6. Rajala MW, Scherer PE 2003 Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144:3765-3773
7. Guerre-Millo M 2004 Adipose tissue and adipokines: for better or worse. Diabetes Metab 30:13-19
8. Abate N, Garg A 1995 Heterogeneity in adipose tissue metabolism: causes, implications and management of regional adiposity. Prog Lipid Res 34:53-70
9. Fried SK, Bunkin DA, Greenberg AS 1998 Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847-850
10. Bergman RN, Van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP, Ellmerer M 2001 Central role of the adipocyte in the metabolic syndrome. J Investig Med 49:119-126
11. Toni R, Malaguti A, Castorina S, Roti E, Lechan RM 2004 New paradigms in neuroendocrinology: relationships between obesity, systemic inflammation and the neuroendocrine system. J Endocrinol Invest 27:182-186
12. Lewis GF, Carpentier A, Adeli K, Giacca A 2002 Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23:201-229
13. Heilbronn L, Smith SR, Ravussin E 2004 Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord 28(Suppl 4):S12-S21
14. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW 2003 Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808
15. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H 2003 Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830
16. Marx N, Duez H, Fruchart JC, Staels B 2004 Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94:1168-1178
17. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML 2000 Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105:271-278
18. Frayn KN, Fielding BA, Karpe F 2005 Adipose tissue fatty acid metabolism and cardiovascular disease. Curr Opin Lipidol 16:409-415
19. Arner P 2005 Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab 19:471-482
20. Kershaw EE, Flier JS 2004 Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548-2556
21. Hauner H 2005 Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 64:163-169
22. Skurk T, Kolb H, Muller-Scholze S, Rohrig K, Hauner H, Herder C 2005 The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol 152:863-868
23. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan J, Gong DW 2006 Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290:E1253-E1261
24. Nedergaard J, Petrovic N, Lindgren EM, Jacobsson A, Cannon B 2005 PPARγ in the control of brown adipocyte differentiation. Biochim Biophys Acta 1740:293-304
25. van Harmelen V, Elizalde M, Ariapart P, Bergstedt-Lindqvist S, Reynisdottir S, Hoffstedt J, Lundkvist I, Bringman S, Arner P 2000 The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int J Obes Relat Metab Disord 24:673-678
26. Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF 2002 Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res 34:616-621
27. He G, Pedersen SB, Bruun JM, Lihn AS, Jensen PF, Richelsen B 2003 Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects. Horm Metab Res 35:178-182
28. Bruun JM, Lihn AS, Madan AK, Pedersen SB, Schiott KM, Fain JN, Richelsen B 2004 Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab 286:E8-E13
29. van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, Arner P 1998 Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 47:913-917
30. Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ, Starcynski J, Crocker J, Barnett AH, McTernan CL, Kumar S 2002 Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res 34:650-654
31. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B 2004 Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 219:9-15
32. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW 2004 Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145:2273-2282
33. Frayn KN 2002 Adipose tissue as a buffer for daily lipid flux. Diabetologia 45:1201-1210
34. Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein SR 2005 Mineralo-corticoid-stimulating activity of adipose tissue. Best Pract Res Clin Endocrinol Metab 19:567-575
35. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T 2001 The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946
36. Chandran M, Phillips SA, Ciaraldi T, Henry RR 2003 Adiponectin: more than just another fat cell hormone? Diabetes Care 26:2442-2450
37. Dietze-Schroeder D, Sell H, Uhlig M, Koenen M, Eckel J 2005 Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 54:2003-2011
38. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE 2000 Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 43:1498-1506
39. Yki-Järvinen H 2005 Fat in the liver and insulin resistance. Ann Med 37:347-356
40. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA 2001 Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935
41. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA 2001 The hormone resistin links obesity to diabetes. Nature 409:307-312
42. Gong H, Ni Y, Guo X, Fei L, Pan X, Guo M, Chen R 2004 Resistin promotes 3T3-L1 preadipocyte differentiation. Eur J Endocrinol 150:885-892
43. Kim KH, Lee K, Moon YS, Sul HS 2001 A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 276:11252-11256
44. Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R, Bouloumié A 2006 Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49:744-747
45. Fernandez-Real JM, Ricart W 2003 Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24:278-301
46. Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH 2005 Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 54:795-802
47. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE 2003 Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459-469
48. Wellen KE, Hotamisligil GS 2003 Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112:1785-1788
49. Wellen KE, Hotamisligil GS 2005 Inflammation, stress, and diabetes. J Clin Invest 115:1111-1119
50. Bouloumié A, Curat CA, Sengenes C, Lolmede K, Miranville A, Busse R 2005 Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 8:347-354
51. Tchoukalova YD, Sarr MG, Jensen MD 2004 Measuring committed preadipocytes in human adipose tissue from severely obese patients by using adipocyte fatty acid binding protein. Am J Physiol Regul Integr Comp Physiol 287:R1132-R1140
52. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante Jr AW 2006 CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115-124
53. Bruun JM, Lihn AS, Pedersen SB, Richelsen B 2005 Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 90:2282-2289
54. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M, Yamauchi T, Ueki K, Oishi Y, Nishimura S, Manabe I, Hashimoto H, Ohnishi Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Nagai R, Kadowaki T 2006 Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 8 281:26602-26614
55. Gustafson B, Smith U 2006 Cytokines promote WNT signaling and inflammation and impair the normal differentiation and lipid accumulation in 3T3-L1 preadipocytes. J Biol Chem 281:9507-9516
56. Zhao T, Hou M, Xia M, Wang Q, Zhu H, Xiao Y, Tang Z, Ma J, Ling W 2006 Globular adiponectin decreases leptin-induced tumor necrosis factor-α expression by murine macrophages: involvement of cAMP-PKA and MAPK pathways. Cell Immunol 238:19-30
57. Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V, Gravanis A, Margioris AN 2005 Adiponectin induces TNF-α and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun 335:1254-1263
58. Trayhurn P 2005 Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 184:285-293
59. Wisse BE 2004 The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15:2792-2800
60. Suganami T, Nishida J, Ogawa Y 2005 A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor α. Arterioscler Thromb Vasc Biol 25:2062-2068
61. Permana PA, Menge C, Reaven PD 2006 Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun 341:507-514
62. Emanuelli B, Glondu M, Filloux C, Peraldi P, Van Obberghen E 2004 The potential role of SOCS-3 in the interleukin-1β-induced desensitization of insulin signaling in pancreatic β-cells. Diabetes 53(Suppl 3):S97-S103
63. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, White MF 2001 Insulin/IGF-1 and TNF-α stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 107:181-189
64. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS 1997 Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99:2416-2422
65. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK 1998 Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95:7614-7619
66. Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, Zawadzki C, Haulon S, Kubaszek A, Koehler C, Leonhardt W, Staels B, Laakso M 2004 Ala12Ala genotype of the peroxisome proliferator-activated receptor γ2 protects against atherosclerosis. J Clin Endocrinol Metab 89:4238-4242
67. Shiraki T, Kamiya N, Shiki S, Kodama TS, Kakizuka A, Jingami H 2005 α,β-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ. J Biol Chem 280:14145-14153
68. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM 2002 The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968-2974
69. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y 2001 PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099
70. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T 2001 The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ(PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 276:41245-41254
71. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA 2004 Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89:4312-4319
72. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA 2004 Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28:783-789
73. Adams M, Montague CT, Prins B, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VKK, O'Rahilly S 1997 Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153
74. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T 1998 Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese zucker rats. J Clin Invest 101:1354-1361
75. Kliewer SA, Xu E, Lambert MH, Willson TM 2001 Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 56:239-263
76. Bogacka I, Xie H, Bray GA, Smith SR 2004 The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo. Diabetes Care 27:1660-1667
77. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF 2001 Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50:1863-1871
78. Hollenberg NK 2003 Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 115(Suppl 8A):111S-115S
79. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA 2002 Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791
80. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA 2005 Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54:24-32
81. Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H 2004 Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176
82. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA 2004 Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89:200-206
83. Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, Kern PA 2005 Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 288:E930-E934
84. Harte AL, McTernan PG, McTernan CL, Smith SA, Barnett AH, Kumar S 2003 Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes Metab 5:302-310
85. Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, Ranganathan G, Peterson CA, McGehee RE, Kern PA 2005 Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 54:2305-2313
86. Hammarstedt A, Andersson CX, Rotter Sopasakis V, Smith U 2005 The effect of PPARγ ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot Essent Fatty Acids 73:65-75
87. Harte A, McTernan P, Chetty R, Coppack S, Katz J, Smith S, Kumar S 2005 Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 111:1954-1961
88. Bouskila M, Pajvani UB, Scherer PE 2005 Adiponectin: a relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity? Int J Obes Relat Metab Disord 29(Suppl 1):S17-S23
89. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE 2004 Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162
90. Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, Tokuyama K, Takamoto I, Mineyama T, Ishikawa M, Moroi M, Sugi K, Yamauchi T, Ueki K, Tobe K, Noda T, Nagai R, Kadowaki T 2006 Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin dependent and independent pathway. J Biol Chem 281:8748-8755
91. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE 2006 Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists. J Biol Chem 281:2654-2660
92. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ GLAI Study Investigators 2005 A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547-1554
93. Buse JB, Tan MH, Prince MJ, Erickson PP 2004 The effects of oral antihyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 6:133-156
94. Matsui J, Terauchi Y, Kubota N, Takamoto I, Eto K, Yamashita T, Komeda K, Yamauchi T, Kamon J, Kita S, Noda M, Kadowaki T 2004 Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-γ-deficient mice on a high-fat diet. Diabetes 53:2844-2854
95. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S 2004 Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 286:E560-E567
96. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC 2005 Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab 90:6678-6686
97. Lalloyer F, Vandewalle B, Percevault F, Torpier G, Kerr-Conte J, Oosterveer M, Paumelle R, Fruchart JC, Kuipers F, Pattou F, Fievet C, Staels B 2006 Peroxisome proliferator-activated receptor α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 55:1605-1613
98. Nesto R 2004 C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 21:810-817
99. Staels B 2005 PPARγ and atherosclerosis. Curr Med Res Opin 21(Suppl 1):S13-S20
100. Li AC, Palinski W 2006 Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Annu Rev Pharmacol Toxicol 46:1-39
101. Chinetti G, Zawadski C, Fruchart JC, Staels B 2004 Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXR. Biochem Biophys Res Commun 314:151-158
102. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T 2005 Peroxisome proliferator-activated receptor (PPAR)α activation increases adiponectin receptors and reduces obesity-related Inflammation in adipose tissue: comparison of activation of PPARα, PPARγ and their combination. Diabetes 54:3358-3370
103. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T 2005 Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45:1925-1931
104. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML 2003 Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278:34268-34276
105. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM 2003 Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 100:15712-15717
106. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR 2003 Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112:608-618
107. Tsuchida A, Yamauchi T, Kadowaki T 2005 Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor γ, CREB-binding protein, and adiponectin. J Pharmacol Sci 97:164-170
108. Kintscher U, Law RE 2005 PPARγ-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab 288:E287-E291
109. Jones JR, Barrick C, Kim KA, Lindner J, Blondeau B, Fujimoto Y, Shiota M, Kesterson RA, Kahn BB, Magnuson MA 2005 Deletion of PPARγ in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci USA 102:6207-6212
110. Moller DE, Berger JP 2003 Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 27(Suppl 3):S17-S21
111. Evans RM, Barish GD, Wang YX 2004 PPARs and the complex journey to obesity. Nat Med 10:355-361